• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Anteris Technologies Global Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    4/23/26 5:13:20 PM ET
    $AVR
    Industrial Specialties
    Health Care
    Get the next $AVR alert in real time by email
    false000201151400020115142026-04-232026-04-23

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    FORM 8-K



    CURRENT REPORT
    Pursuant to Section 13 OR 15(d)
    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 23, 2026



    Anteris Technologies Global Corp.
    (Exact name of registrant as specified in its charter)



    Delaware
    001-42437
    99-1407174
    (State or Other Jurisdiction of Incorporation)
    (Commission File Number)
    (I.R.S. Employer Identification No.)

    Toowong Tower, Level 3, Suite 302
    9 Sherwood Road
    Toowong, QLD
    Australia

    4066
    (Address of Principal Executive Offices)

    (Zip Code)

    Registrant’s telephone number, including area code: +61 7 3152 3200

    Not Applicable
    (Former name or former address, if changed since last report)



    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading
    Symbol(s)

    Name of each exchange
    on which registered
    Common Stock, par value $0.0001 per share

    AVR

    The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 1.01.
    Entry into a Material Definitive Agreement.
     
    Lease Agreement

    On April 23, 2026, Anteris Technologies Global Corp., through its wholly owned subsidiary, Anteris Technologies Corporation (the “Company”), entered into a lease agreement (the “Lease”) with Northcross West Industrial Owner, LLC (“Northcross”) for approximately 181,436 square feet of space in an office and warehouse facility located in Brooklyn Park, Minnesota.
     
    The Lease has an initial term commencing September 1, 2026 and expiring August 31, 2037 and may be extended for two periods of 84 months each at market rent, subject to other terms and conditions set forth therein. Under the Lease, the Company is required to pay monthly minimum rent initially of $152,708.63, subject to contractual rent abatements, annual escalations and other adjustments as provided in the Lease, plus real estate taxes, operating expenses and other charges. Rent for the first three months of the Lease will be completely abated so long as the Company is not in default of the lease and rent for the succeeding nine months will be partially abated.
     
    The foregoing description does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2026.
     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Anteris Technologies Global Corp.


    Date: April 23, 2026






    By:
    /s/ Wayne Paterson

    Name:
    Wayne Paterson

    Title:
    Vice Chairman and Chief Executive Officer



    Get the next $AVR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVR

    DatePrice TargetRatingAnalyst
    3/12/2026$15.00Overweight
    Cantor Fitzgerald
    3/11/2026$16.00Overweight
    Wells Fargo
    1/8/2025$20.00Buy
    Lake Street
    1/7/2025$15.00Buy
    TD Cowen
    1/7/2025$9.00Overweight
    Cantor Fitzgerald
    1/7/2025$22.00Overweight
    Barclays
    More analyst ratings

    $AVR
    SEC Filings

    View All

    Anteris Technologies Global Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Anteris Technologies Global Corp. (0002011514) (Filer)

    4/23/26 5:13:20 PM ET
    $AVR
    Industrial Specialties
    Health Care

    SEC Form 424B3 filed by Anteris Technologies Global Corp.

    424B3 - Anteris Technologies Global Corp. (0002011514) (Filer)

    3/18/26 8:46:48 AM ET
    $AVR
    Industrial Specialties
    Health Care

    SEC Form EFFECT filed by Anteris Technologies Global Corp.

    EFFECT - Anteris Technologies Global Corp. (0002011514) (Filer)

    3/16/26 12:15:06 AM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald resumed coverage on Anteris Technologies Global Corp. with a new price target

    Cantor Fitzgerald resumed coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $15.00

    3/12/26 8:49:18 AM ET
    $AVR
    Industrial Specialties
    Health Care

    Wells Fargo initiated coverage on Anteris Technologies Global Corp. with a new price target

    Wells Fargo initiated coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $16.00

    3/11/26 8:36:17 AM ET
    $AVR
    Industrial Specialties
    Health Care

    Lake Street initiated coverage on Anteris Technologies Global Corp. with a new price target

    Lake Street initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $20.00

    1/8/25 8:52:46 AM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner L1 Capital Pty Ltd bought $28,750,000 worth of shares (5,000,000 units at $5.75) (SEC Form 4)

    4 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    2/9/26 8:49:36 PM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anteris Reports 2025 Financial Results and Provides Corporate Update

    MINNEAPOLIS and BRISBANE, Australia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the full year ended December 31, 2025, and provided a corporate update. 2025 Full Year Highlights & Recent Developments Initiated the global pivotal PARADIGM Trial, building on experience from successfully treating 130 patients with the DurAVR® THV, including de novo (first time) aortic stenosis cases, complex anatomies and valve-in-valve p

    2/26/26 6:00:00 PM ET
    $AVR
    Industrial Specialties
    Health Care

    Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays

    MINNEAPOLIS and BRISBANE, Australia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson will be presenting at both the TD Cowen 46th Annual Healthcare Conference and the Barclays 28th Annual Healthcare Conference. The details of each conference and how to access them are as follows: TD Cowen 46th Annual Healthcare Conference Date:Monday, March 2nd, 2026 (US time)Format:Fireside chat wi

    2/23/26 6:30:00 AM ET
    $AVR
    Industrial Specialties
    Health Care

    Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises

    MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has completed a $90 million strategic investment from Medtronic, plc (Galway, Ireland) (NASDAQ:MDT) (Medtronic), the world's largest medical technology company. The investment closed immediately following Anteris' underwritten offering of common stock, for a combined $320 million in gross proceeds, which supports execution of the global pivotal PARADIGM trial and advan

    1/22/26 4:02:00 PM ET
    $AVR
    $MDT
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $AVR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Mcdonnell Matthew

    4 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    3/6/26 4:51:03 PM ET
    $AVR
    Industrial Specialties
    Health Care

    Large owner L1 Capital Pty Ltd bought $28,750,000 worth of shares (5,000,000 units at $5.75) (SEC Form 4)

    4 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    2/9/26 8:49:36 PM ET
    $AVR
    Industrial Specialties
    Health Care

    New insider Medtronic Plc claimed ownership of 15,652,173 shares (SEC Form 3)

    3 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    1/29/26 4:11:39 PM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Leadership Updates

    Live Leadership Updates

    View All

    Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

    MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

    6/9/25 10:52:06 PM ET
    $AVR
    $LMAT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments